🇺🇸 FDA
Pipeline program

Bimatoprost

SPON 1266-14

Approved small_molecule completed

Quick answer

Bimatoprost for Graves' Ophthalmopathy is a Approved program (small_molecule) at Cardiff Oncology with 1 ClinicalTrials.gov record(s).

Program details

Company
Cardiff Oncology
Indication
Graves' Ophthalmopathy
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials